TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
Go back to TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma| Johnson & Johnson (NYSE: JNJ) | Delayed: 269.47 -0.52 (0.19%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $269.99 | 52 Week High | $126.07 | |||
| Open | $271.74 | 52 Week Low | $94.28 | |||
| Day High | $273.73 | P/E | 56.02 | |||
| Day Low | $268.50 | EPS | $4.81 | |||
| Volume | 4,485,347 | |||||
